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The role of the immune system is to restore functionality in response to stress. Increasing evidence shows
that this function is not limited to insults by infection or injury and plays a role in response to overnutrition.
Initially, this metabolic activation of the immune system is a physiological response, but it may become dele-
terious with time. Therefore, therapeutic interventions should aim at modulating the immune system rather
than simply damping it. In this article, we describe the physiology and pathology of the immune system dur-
ing obesity and diabetes with a focus on islet inflammation, the IL-1b pathway, and clinical translation.Introduction
Traditionally, the metabolism and the immune system were
perceived as two distinct entities with different functions (nutrient
disposal and host defense, respectively). This led to separate
specialized research tracks with little interaction between the
two fields. In the clinic, interplay between the two systems is often
observed. Indeed, steroid hormonesarepotent immunesuppres-
sors and strong inducers of hyperglycemia. Fever is associated
with profound changes in metabolism. Some chronic infections
may cause a wasting syndrome. More recently, markers of the
acute-phase response, including sialic acid, alpha-1 acid glyco-
protein, serum amyloid A, C-reactive protein (CRP) and cortisol,
and interleukin (IL)-6 were associated with type 2 diabetes and
cardiovascular disease (Pickup and Crook, 1998; Pickup et al.,
1997; Pradhan et al., 2001; Spranger et al., 2003). In parallel to
thesewell-established associations, an increasing number of sci-
entistsworking on themultiple disorders characterizing themeta-
bolic syndromeobserved that several of its featuresmay be regu-
lated by a pathological activation of the immune system. This
holds true for insulin resistance (Hotamisligil et al., 1993), insulin
secretion defects (Maedler et al., 2002b), and complications of
type 2 diabetes such as cardiovascular (Berk et al., 1990; Ridker
et al., 1997) or kidney diseases (Navarro-Gonza´lez andMora-Fer-
na´ndez, 2008). Therefore, type 2 diabetes can be considered as
an inflammatory disease (Donath and Shoelson, 2011).
Beyond these pathological aspects, the involvement of the
immune system in the regulation of metabolism may have a pri-
marily physiological role. By definition, the immune system is a
system of biological structures and processes within an organ-
ism that protects against disease. Such an involvement may
also play a role in metabolism. Indeed, several observations
point to a beneficial role of the immune system in the adaption
to changes in nutrient availability (Ellingsgaard et al., 2011; Mae-
dler et al., 2006). Therefore, we propose that the immune
response to an increased amount of nutrients is an adaptive
reaction to cope with these changes. Depending on the duration
and the degree of metabolic stress, this activation of the immune
system may become deleterious. In this article, we will discuss
the role of the immune system as a regulator of metabolism,
for the good and for the bad, with a focus on islet inflammation,
the IL-1b pathway, and clinical translation.860 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.The Immune System in the Physiological Adaptation
of Insulin Production and Secretion
Inflammation is not a disease in itself, but rather a manifestation
of a disease. Initially, it has beneficial effects such as preventing
the spread of infection or promoting regeneration. However, if
prolonged or excessive, it may exacerbate disease by tissue
destruction. It is likely that, in the case of islet inflammation in
type 2 diabetes, similar phenomena occur. Indeed, the endo-
crine pancreas may adapt to conditions of increased insulin
demand (as encountered in obesity and pregnancy) by
increasing its functional mass. This may be triggered by limited
hyperglycemic events that provoke b cell production of low con-
centrations of IL-1b followed by Fas upregulation (Maedler et al.,
2002a; Maedler et al., 2006). At these concentrations of IL-1b
and in the presence of FLICE-like inhibitory protein (FLIP), Fas
engagement leads to b cell proliferation and enhanced function
via NF-kB and pancreatic and duodenal homeobox 1 (PDX1)
(Schumann et al., 2007).
Another example of a physiological role of the immune system
is IL-6. The role of IL-6 in the context of glucose metabolism is
unclear, and there is an ongoing debate regarding whether IL-6
is deleterious or beneficial (Carey et al., 2006; Jansson and Wal-
lenius, 2007; Lazar, 2005; Mooney, 2007; Pedersen and Feb-
braio, 2007; Sabio et al., 2008; Weigert et al., 2007; Wunderlich
et al., 2010). In support of a deleterious role of IL-6, systemic
IL-6 levels are elevated in obese individuals and in patients
with type 2 diabetes, and these elevated IL-6 levels predict dis-
ease development (Pradhan et al., 2001; Spranger et al., 2003).
However, the seminal discovery that skeletal muscle produces
and releases IL-6 in response to muscle contraction has chal-
lenged the hypothesis that IL-6 is deleterious (Febbraio and Ped-
ersen, 2002). Yet, despite efforts to pinpoint the physiological
role of exercise-induced IL-6, this remains to be elucidated fully
(Pedersen and Fischer, 2007). IL-6 is necessary for a cell mass
expansion after high-fat diet (HFD) feeding (Ellingsgaard et al.,
2008). Furthermore, HFD feeding of IL-6 knockout mice results
in increased fed glycemia due to impaired insulin secretion,
with unchanged insulin sensitivity and similar body weights.
Thus, IL-6 is necessary for the expansion of the pancreatic
a cell mass in response to HFD feeding, and this expansion may
be a compensatory mechanism required for the maintenance of
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it was shown that elevated circulating IL-6 levels increase
plasma levels of the incretin hormone glucagon-like peptide-1
(GLP-1), improving insulin secretion and glucose tolerance.
Furthermore, IL-6 induced GLP-1 production and secretion
from intestinal L cells and the pancreatic a cells. Hence, IL-6
mediates crosstalk between insulin-sensitive tissues, L cells,
and pancreatic islets to adapt to changes in insulin demand by
increasing GLP-1 secretion and reprogramming the a cells to
process proglucagon to GLP-1.
Overall these studies demonstrate that components of the
innate immune system may have very precise roles in the adap-
tation of the metabolism. It is expected that many more factors
are implicated in this physiological role of the immune system.
What Triggers the Innate ImmuneSystemduringObesity
and in Patients with Type 2 Diabetes?
In All Organs
In obese and insulin-resistant individuals, intake of large
amounts of carbohydrates leads to transiently elevated glucose
levels defined as impaired glucose tolerance. With time, this pre-
diabetes state may progress to chronic hyperglycemia (i.e., dia-
betes). Additionally, elevated concentrations of other circulating
nutrients, such as free fatty acids (FFAs), are observed in obesity
and type 2 diabetes (Boden, 1997). In parallel to increased
nutrient concentrations, inflammation is observed in all tissues
involved in energy homeostasis, including fat, muscle, liver,
and islets, as well as in the nutrient-transporting blood vessels
(Berk et al., 1990; Hotamisligil et al., 1993; Maedler et al.,
2002b; Navarro-Gonza´lez and Mora-Ferna´ndez, 2008; Ridker
et al., 1997; Wellen and Hotamisligil, 2005). This association
between metabolic stress and inflammation suggests a causal
link, which is now supported by experimental data. In vitro
FFAs are proinflammatory in many cell types, particularly the
saturated long-chain FFAs palmitate (C16:0) and stearate
(C18:0) but also the monounsaturated oleate (C18:1), which alto-
gether constitute 80% of the circulating FFAs in humans, while
short-chain FFAs (<C14) appear not active with respect to
inflammation (Lee et al., 2004; Nguyen et al., 2007; Senn,
2006; Shi et al., 2006; Song et al., 2006). Two main types of
mechanisms explaining FFA-triggered inflammation have been
proposed, toll-like receptor (TLR)-dependent and TLR-
independent types. TLRs are pattern recognition receptors of
the innate immune system that can be stimulated by numerous
bacterial wall products such as lipopolysaccaride (LPS)-contain-
ing long-chain fatty acid moieties. Therefore, it has been postu-
lated that FFAs directly bind to TLRs and thereby induce a
proinflammatory response (Lee et al., 2001, 2004). However,
recent evidence ruled this out (Schaeffler et al., 2009), and
several indirect ways in which FFAs engage TLRs were
described. It was reported that FFAs induce the formation of lipid
rafts in cell membranes, favoring dimerization of TLRs required
for signaling (Holzer et al., 2011; Wong et al., 2009). Others
postulated the involvement of an endogenous ligand linking
FFA to TLR. An example is the fatty acid transporter CD36, which
binds to TLR2 (Seimon et al., 2010). Recently, the liver-derived
glycoprotein fetuin-A was identified as the endogenous ligand
linking FFA and TLR4, causing inflammation and insulin resis-
tance (Pal et al., 2012). Further, lipid-mediated toxicity may pro-mote damage signals such as high-mobility group protein 1.
These are then recognized by TLRs that activate proinflamma-
tory pathways (Park et al., 2004). TLR-independent activation
of inflammatory pathways by FFAs involves the production of
reactive oxygen species (ROS), which in turn induce stress
kinases. ROSmay also lead to the formation of NLRP3 inflamma-
somes, which activates the IL-1 system (Wen et al., 2011). In line
with such a mechanism, it was observed in human and mouse
islets that the induction of a broad proinflammatory response
by FFAs predominantly depends on IL-1 receptor activation.
Blocking IL-1 receptor signaling in human islets with the natural
receptor antagonist IL-1Ra or the neutralizing anti-IL-1b
antibody completely inhibited the induction of cytokines and
chemokines by FFAs (Bo¨ni-Schnetzler et al., 2009). That both
TLR-dependent and -independent mechanisms may operate in
concert is indicated by the finding that TLR2- or TLR4-deficient
mouse islets are only partially protected from FFA-induced
proinflammatory cytokine induction, while the lack of Myd88,
which is a universal intracellular docking protein required for
both TLR and IL-1 receptor signaling, was fully protective
(Bo¨ni-Schnetzler et al., 2009).
In vivo short-term infusion of FFAs in rodents or a single fatty
meal in humans results in the induction of proinflammatory cyto-
kines and chemokines. In rats, a 2 day infusion with a triglyceride
emulsion together with heparin, which results in the breakdown
(of triglyceride) into FFAs and a 2-fold increase in plasma
FFAs, induces the expression of proinflammatory factors in islets
and increases plasma cytokine levels (Tang et al., 2013). Further,
infusion of palmitate for only 14 hr inmice induced chemokines in
islets and recruited macrophages in a TLR4- and Myd88d-
dependent manner (Eguchi et al., 2012). In humans, the con-
sumption of a single high-fat meal increased circulating IL-18
levels (Esposito et al., 2003).
Besides FFAs, elevated glucose levels may also elicit a sys-
temic inflammatory response (Deopurkar et al., 2010). Two
mechanisms have been proposed to explain this phenomenon.
First, chronic hyperglycemia results in nonenzymatic glycation
of proteins and lipids, leading to advanced glycation end prod-
ucts (AGEs), which in turn stimulate the pattern recognition
receptor RAGE. RAGE engagement activates the proinflamma-
tory transcription factor NF-kB and stress kinases ERK1 and
ERK2 and induces further ROS production (Bierhaus and
Nawroth, 2009). RAGE is expressed on various cell types such
as macrophages, smooth muscle cells, T cells, podocytes, car-
diomyocytes, and neuronal cells (Yan et al., 2009). The second
mechanism involves ROS that are formed when excessive
glucose is metabolized to ATP via oxidative phosphorylation
(Zhou et al., 2010). ROSmay then activate the NLRP3 inflamma-
some in concert with FFAs, leading to the release of active IL-1b
and production of IL-1-dependent cytokines and chemokines
(Bo¨ni-Schnetzler et al., 2009).
In Islets
The first evidence for an inflammatory process in the pancreatic
islet arose from the observation that hyperglycemia induces
b cell apoptosis (Donath et al., 1999). Unraveling the underlying
mechanism (Figure 1), it turns out that high-glucose concentra-
tions induce the Fas receptor, which is upregulated via
glucose-induced IL-1b production (Maedler et al., 2001, 2002a,
2002b). Similarly, recent evidence shows that fatty acids alsoCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 861
Figure 1. Innate Immune Response to
Metabolic Stress in Pancreatic Islets
Increased circulating free fatty acids (FFA), modi-
fied LDL (mLDL) particles, and advanced glycation
end products (AGE) bind to their cognate
receptors (i.e., Toll-like receptor 2 [TLR2], TLR4,
and RAGE, respectively), leading to NF-kB acti-
vation and the production of various proin-
flammatory chemokines and cytokines, including
the proform of IL-1b. Furthermore, high concen-
trations of glucose promote the activation of the
NLRP3 inflammasome through the recruitment of
thioredoxin-interacting protein (TXNIP) in both
b cells andmacrophages. FFA and AGE, as well as
islet-derived islet amyloid polypeptide (IAPP), may
also directly trigger the NLRP3 inflammasome
complex. Subsequently, pro-IL-1b is processed
by the NLRP3-associated caspase-1 and
secreted in the microenvironment. In turn, IL-1b
sustains autocrine and paracrine activation of both
b cells and macrophages, exacerbating the
chronic inflammatory responses in the islets.
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Ehses et al., 2007; and see above). In support of insulitis in type 2
diabetes, elevated numbers of immune cells have been detected
in islets of patients with type 2 diabetes and in animal models in
conjunction with increased levels of cytokines and chemokines
(Bo¨ni-Schnetzler et al., 2008; Ehses et al., 2007; Richardson
et al., 2009) (Figure 2B). Of note, every animal model of type 2
diabetes investigated to date displays islet immune cell infiltra-
tion (Ehses et al., 2007, 2009a). Furthermore, a strong argument
for the occurrence of an inflammatory process in islets is the
well-described fibrosis observed in tissue sections of patients
with type 2 diabetes, characterized by amyloid deposits. Indeed,
fibrosis is a hallmark of the end stage of a chronic inflammatory
process. Of interest is the predominant role of IL-1b, which is
upregulated in islets of patients with type 2 diabetes (Bo¨ni-
Schnetzler et al., 2008; Maedler et al., 2002b). This master cyto-
kine regulates numerous other cytokines and chemokines
(Dinarello, 2009; Ehses et al., 2009b). Thereby, it contributes to
the recruitment of immune cells implementing a broad inflamma-
tory response. It is notable that IL-1b will also induce itself in
b cells, engendering a vicious cycle (Bo¨ni-Schnetzler et al.,
2008). Thus, insulitis may be considered as a fundamental part
of the pathogenesis of type 2 diabetes.
Islet b cells have mitochondrial activity 2- to 3-fold higher than
any other cell, due to the blood glucose sensing and coupling to
insulin secretion viaglucoseoxidation inmitochondria. Therefore,
they areprone to increasedROSproduction. Thismayexplain the
susceptibility of b cells to glucose-induced IL-1b (Maedler et al.,
2002b). Indeed, ROS leads to the dissociation of a complex
consisting of thioredoxin and thioredoxin-interacting protein
(TXNIP) and to thebindingof the liberatedTXNIP toNLRP3,which
initiates the formationof the inflammasome (Zhouet al., 2010) and
thus secretion of IL-1b. A combination of elevated glucose
togetherwith FFAs is evenmore effective in inducing a proinflam-
matory phenotype in human islets (Bo¨ni-Schnetzler et al., 2009)
and human monocytes (Dasu and Jialal, 2011).
The flux of proteins through the endoplasmic reticulum of
b cells is high under normal conditions and increases in the
face of insulin resistance. Therefore, endoplasmic reticulum
stress may play a role in islet b cell dysfunction in type 2 diabetes862 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.(Harding and Ron, 2002). Interestingly, TXNIP is induced by
endoplasmic reticulum stress, leading to NLRP3-dependent
IL-1b production by b cells (Oslowski et al., 2012).
In support of a specific role for IL-1b in islet inflammation, a
recent, unbiased analysis of the global gene expression in
human pancreatic islets revealed that a group of coexpressed
genes (module), enriched for IL-1-related genes, was associated
with type 2 diabetes and reduced insulin secretion (Mahdi et al.,
2012). Interestingly, one of the module genes that was highly
overexpressed is SFRP4, which encodes secreted frizzled-
related protein 4 and may mediate IL-1b effects on islet.
Another specificity of the human pancreatic islets is the depo-
sition of islet amyloid polypeptide (IAPP), which is a typical
feature of more than 90% of islets from patients with type 2 dia-
betes. IAPP is a 37 amino acid long peptide, which (like insulin) is
processed by PC1/3 and PC2 from a proform to the mature form
and then cosecreted with insulin. Human IAPP rapidly forms ag-
gregates and fibrils, resulting in amyloid depositions. In contrast,
rodent IAPP does not aggregate, and only overexpression of the
human IAPP in mice and rats results in b cell dysfunction (for
review see Westermark et al., 2011). NLRP3 inflammasome
formation is reported to be induced by a growing list of com-
pounds, such as urea crystals or asbestos (Hornung et al.,
2008; Martinon et al., 2006), and human IAPP was added to
the list recently (Masters et al., 2010). Oligomeric human IAPP
together with a second trigger induces inflammasome formation
and consecutive IL-1b secretion in bonemarrow-derivedmacro-
phages. This second trigger was either LPS orminimally oxidized
low-density lipoproteins. Interestingly, fibrils were less effective
than oligomers in these macrophages. Further, expression of
elevated IL-1b was observed in islets of mice producing human
IAPP, suggesting that IAPP may indeed trigger IL-1b production
(Masters et al., 2010). This is supported by observations with a
transplantation model in which hIAPP-expressing islets were
transplanted to NOD/Scid mice treated with or without the IL-1
receptor antagonist IL-1Ra. IL-1Ra protected transplanted
hIAPP-expressing islets from the deterioration of glucose
homeostasis in mice transplanted with hIAPP-expressing islets,
suggesting that human IAPP impairs b cells via the IL-1 pathway
(Westwell-Roper et al., 2011).
Figure 2. Representative Staining of CD68-
Positive Macrophages in Adipose Tissue or
Pancreas of Obese Patients with Type 2
Diabetes
(A) Macrophages can be found isolated (arrow)
between adipocytes or typically organized in a
crown-like structure (*) surrounding a dead-like
adipocyte.
(B) Macrophages are isolated and dispersed
throughout and around the pancreatic islet
(black line).
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For two decades now, experimental and clinical data have
clearly established that adipose tissue itself is a site of inflamma-
tion during obesity. Since the seminal discovery of increased
production of tumor necrosis factor alpha (TNF-a) in adipose tis-
sue of obese mice (Hotamisligil et al., 1993), specific upregula-
tion of genes encoding inflammatory factors have become key
features of enlarged adipose tissue. More recently, adipose tis-
sue was associated with amarked accumulation of immune cells
during obesity (Weisberg et al., 2003; Wu et al., 2007; Xu et al.,
2003) (Figure 2A). However, the events that initiate local inflam-
mation are unclear and could involve different, but synergetic,
mechanisms (Figure 3). Adipocytes themselves may produce
cytokines and chemokines in response to changes in their cell
size (Skurk et al., 2007). Eventually, hypertrophy may lead to
adipocyte death and release of cellular contents into the extra-
cellular space, triggering an inflammatory response. In partic-
ular, macrophages are observed surrounding moribund or
dead-like adipocytes in crown-like structures (Cinti et al., 2005;
Weisberg et al., 2003; Xu et al., 2003). Progressive lipid accumu-
lation also contributes to the alternative anti-inflammatory
M2-to-proinflammatory M1 phenotypic switch in macrophages
that occurs in adipose tissue of obese mice (Prieur et al., 2011;
Weisberg et al., 2003; Xu et al., 2003). Indeed, adipocyte-derived
FFAs or ceramides induce inflammatory responses in macro-
phages mainly through TLR- or NLRP3-dependent pathways
(Nguyen et al., 2007; Vandanmagsar et al., 2011). It has also
been proposed that local hypoxia, as a result of vasculature
insufficiency in expanding adipose tissue, stimulates inflamma-
tory gene expression in both adipocytes and immune cells
(reviewed in Ye, 2009). However, this hypothesis could not yet
be confirmed fully in human obesity (Goossens et al., 2011).
Alternatively, cellular stress responses, such as the reticulum
endoplasmic stress and related autophagy, may be at the origin
of local inflammatory signaling pathways in adipose tissue dur-
ing obesity (reviewed in Hotamisligil, 2010 and in this issue of
Cell Metabolism by Martinez et al., 2013). Finally, other factors,
such as the incretin hormone glucose-dependent insulinotropic
peptide, may play a role (Nie et al., 2012; Timper et al., 2013).
In Blood Vessels
Atherosclerosis has long been linked to obesity and dyslipidemia
based on a strong clinical relationship between low-density lipo-
protein (LDL) levels and atheromatous plaque formation. Classi-
cally, proliferation of smooth muscle cells, accumulation of
lipids, and connective tissue characterized the pathogenesis ofatherosclerosis. However, the involvement of inflammation in
atherosclerosis has been recognized for decades (for review,
see Galkina and Ley, 2009; Hansson and Jonasson, 2009; Libby,
2012). Although multiple mechanisms initiate and sustain the
underlying inflammatory process, we will focus on IL-1b in this
part (Figure 4). Galea et al. (1996) found that IL-1b is present in
coronary arteries of patients with ischemic heart disease and
that the amount correlates with the severity of the atheroscle-
rosis. In addition, human plaques overexpress caspase-1 (also
functionally termed IL-1b-converting enzyme; Geng and Libby,
1995). Studies in mice confirmed the role of IL-1b (Elhage
et al., 1998) and revealed mechanistic insights, (e.g., knocking
out IL-1b in ApoE/ mice attenuated atherosclerosis by
reducing the levels of vascular cell adhesion molecule-1 and
monocyte chemotactic protein-1; Kirii et al., 2003). In 2010,
cholesterol crystals were identified as a proinflammatory trigger
during atherogenesis (Duewell et al., 2010). Cholesterol crystals
are a hallmark of atherosclerotic lesions; however, they were
thought to be inert and arise only late in the disease. Since the
crystals dissolve in organic solvents used in histology, their pres-
ence could only be verified by the remaining clefts, of which only
large clefts in advanced lesions were identifiable. In their study,
Duewell et al. (2010) used a new microscope technique that
allowed them to visualize the crystals themselves. They
observed that cholesterol crystals emerge at a very early time
point of atherogenesis at the same time as immune cells.
In vitro, crystallized cholesterol induces the release of IL-1b in
macrophages, which depends on the NLRP3 inflammasome-
containing ASC and caspase-1. They show that the macro-
phages internalize the crystals via phagocytosis, leading to the
rupture of lysosomes and leakage of the proteolytic content
into the cytosol, which is sensed by the NLRP3 inflammasome
by a currently unknown mechanism. Freigang et al. (2011)
demonstrate that not only is IL-1b secreted by mouse macro-
phages in response to cholesterol crystals, but IL-1a is also
secreted in a caspase-1/NLRP3-independent manner. The
induction of both cytokines and their ability to promote athero-
sclerosis depend upon the NF-E2-related factor 2 (Nrf2). Nrf2
plays a role as a defense mechanism against oxidative stress
by increasing antioxidant enzymes; therefore, Nrf2 links oxida-
tive stress to vascular inflammation. In human macrophages,
cholesterol crystals have comparable effects (Duewell et al.,
2010; Rajama¨ki et al., 2010). Taken together, cholesterol crystals
emerge as an endogenous danger signal in mice and humans,
triggering inflammation via the inflammasome-IL-1 axis, andCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 863
Figure 3. Activation of the Immune System
in Adipose Tissue during Obesity
Adipocytes store excessive nutrient load and
progressively become hypertrophic. Cell hyper-
trophy leads to a proinflammatory response
mainly through hypoxia and endoplasmic reticu-
lum (ER) stress-related mechanisms. Eventually,
this may lead to adipocyte death. Furthermore,
stressed adipocytes produce a wide range of
cytokines and chemokines, including TNF-a, that
in turn promote immune cell accumulation and
activation in adipose tissue. Therein, numerous
macrophages create a local proinflammatory loop
with adipocytes. Other immune cells, such as
T cells, might also contribute to inflammation. In
parallel, circulating FFAs and mLDL particles may
directly bind to TLR2 and TLR4, inducing NF-kB
activation and production of various proin-
flammatory factors including pro-IL-1b. In the
meantime, hyperglycemia promotes the activa-
tion of the NLRP3 inflammasome through the
binding of TXNIP in macrophages. Lipid species
such as ceramides may directly activate the
inflammasome. The NLRP3-caspase-1 complex
promotes IL-1b secretion through cleavage of the
proform. IL-1b strongly contributes to adipose
tissue inflammation through autoamplification and
paracrine activation during obesity.
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vascular inflammation that promotes atherosclerosis.
From Innate to Specific Immunity
The current classification of diabetes distinguishes between the
autoimmune type 1 diabetes and the adiposity-associated type
2 diabetes. However, in the clinic an overlap exists inmany cases
of diabetes, and a clear classification is not feasible. Indeed, no
single clinical feature or diagnostic parameter completely
discriminates the two diseases. This includes age, body mass
index, decreased insulin secretion, and insulin resistance.
Thus, nowadays type 2 diabetes is diagnosed at a younger
age, and increased body mass index has been associated with
the observed raise in the incidence of type 1 diabetes. Further,
a progressive decrease in functional b cell mass is evident in
type 2 diabetes, and although it is not typical to find insulin resis-
tance in patients with type 1 diabetes, its prevalence may be
underestimated (Wentworth et al., 2009). Also, the etiology of
both types of diabetes is blurring: at least 10% of patients with
type 2 exhibit b cell-specific antibodies, and some even exhibit
T cells reactive to b cell antigens (Brooks-Worrell et al., 2011),
arguing for an involvement of autoimmunity in islets not only in
type 1, but also in type 2, diabetes.
Genetic support for the overlap is the recent description of a
monogenic form of diabetes with the typical features of type 1
diabetes (autoantibodies to b-cells, lean and young at onset of
hyperglycemia, rapid disappearance of C-peptide production,
and insulin dependence) together with insulin resistance (Bia-
son-Lauber et al., 2013). This disease is the consequence of an
autosomal-dominant mutation in the SIRT1 gene. The disease
pathologymayarise as acombined consequenceofbcell impair-
ment anddeath, alongwith subsequent pathological activation of
the immune system. Indeed, in the presence of insulin resistance,
stressmayacceleratebcell death,whichmay result in the release
of autoantigens together with endogenous danger signals (alar-
mins) capable of promoting pathologic self-antigen presentation864 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.(Zhang et al., 2009). These observations identify a novel role for
SIRT1 as a regulator of immune and metabolic functions in
humans, thereby linking metabolism to autoimmunity. It is note-
worthy that other sirtuinsmayplay a similar role. Indeed, a cellular
pathway linking SIRT2 to cytoskeleton remodeling and activation
of NLRP3 has been identified recently (Misawa et al., 2013).
At a cellular level, complementary to an ongoing activation of
the innate immune compartment, the concept that adaptive
immune cells also contribute to obesity-induced inflammation
is nowestablished. T cells accumulate in adipose tissue concom-
itant with early insulin resistance (Rocha et al., 2008; Wu et al.,
2007). Mouse models of obesity are associated with increased
numbers of cytotoxic CD8+ T effector cells and unchanged or
reduced overall CD4+ helper cells in adipose tissue (Nishimura
et al., 2009). As conductors of the adaptive immune responses,
different CD4+ T helper (Th) lineages exist. Among proinflamma-
tory subsets, classical Th1 and Th17, characterized by secretion
of interferon (IFN)-g and IL-17, respectively, are enriched in the
circulation and adipose tissue of obesemice andmorbidly obese
subjects (Bertola et al., 2012; Duffaut et al., 2009; Jagannathan-
Bogdan et al., 2011; Rocha et al., 2008; Zu´n˜iga et al., 2010).
Inflammatory and metabolic improvements were achieved in
CD8-, IFN-g-, and (to a lesser extent) IL-17-deleted mice fed a
high-fat diet (Rocha et al., 2008; Zu´n˜iga et al., 2010). On the
contrary, the numbers of both anti-inflammatory Th2 and regula-
tory T cells (Foxp3+Tregs) were decreased in the adipose tissue
of obesemousemodels (Feuerer et al., 2009). More interestingly,
humoral immunity with B cell contribution to adipose tissue
inflammation was recently brought to light. B cell knockout or
anti-CD20 therapy significantly improved the metabolic pheno-
type and adipose tissue inflammation in mice fed a high-fat diet
compared to chow-fed mice (Winer et al., 2011).
Clinical Translation
Based on the information above, it is likely that the immune sys-
tem plays a significant role in the regulation of metabolism. The
Figure 4. Activation of Innate Immune
Responses in the Atheroma
Circulating LDL undergo oxidation in the
subendothelial space, from minimally modified
LDL (mmLDL) to extensively oxidized LDL
(oxLDL). Uptake of oxLDL through scavenger
receptors leads to the intracellular storage of
cholesterol crystals that can activate the NLRP3
inflammasome through the transcription factor
Nrf2, leading to IL-1b secretion. FFAs and mLDL
particles can also bind directly to TLRs, leading to
the expression of numerous proinflammatory
genes such as cytokines and chemokines. These
factors, including IL-1b, activate endothelial cells
of the vasculature, triggering the production of
chemokines and adhesion molecules and, subse-
quently, other immune cell migration.
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iological mechanisms are in the development and treatment of
type 2 diabetes compared to other pathways. An increasing
amount of clinical data may provide answers (Table 1).
TNF-a
Since the initial observation of a potential role for TNF-a in the
pathogenesis of insulin resistance and type 2 diabetes (Hotami-
sligil et al., 1993), numerous clinical trials have attempted to sup-
port these preclinical findings. First clinical trials using TNF
blockade failed to demonstrate beneficial effects on glucose
metabolism (Bernstein et al., 2006; Dominguez et al., 2005; Lo
et al., 2007; Ofei et al., 1996; Paquot et al., 2000; Rosenvinge
et al., 2007). However, these studies comprised a very limited
number of individuals and were conducted only for a short-
term period. Because of interindividual variations due to genetic
background, possible changes in eating and exercise habits,
and the chronicity of the inflammatory changes, these studies
were clearly under powered and not designed to allow conclu-
sions about the potential of TNF-a antagonism. Indeed, other
studies conducted with obese subjects or patients being treated
for additional conditions such as rheumatoid arthritis suggest
that TNF-a blockade may alter insulin sensitivity or glycemic
parameters (Kiortsis et al., 2005; Stanley et al., 2011; Yazdani-
Biuki et al., 2004, 2006). Therefore, well-designed studies are
warranted.
Interleukin-1b
The inflammasome appears as the sentinel, sensing metabolic
stress and alarming the immune defense in pancreatic islets,
insulin-sensitive tissues, and blood vessels. If chronically acti-
vated, the resulting production of IL-1b will impair insulin secre-
tion and action. Based on the above observations, numerous
clinical studies have been conducted (Cavelti-Weder et al.,
2012; Larsen et al., 2007, 2009; Ridker et al., 2012; Rissanen
et al., 2012; Sloan-Lancaster et al., 2013; van Asseldonk et al.,
2011). All of these studies have shown beneficial effects on bloodCell Metabolismglucose levels, b cell secretory function,
and/or insulin sensitivity. The observed
effects depend on starting glycated he-
moglobin, concomitant treatment, and
pharmacokinetic characteristics, among
others. Thus, improvement of glycated
hemoglobin varied from 0.2%, which isconsidered clinically irrelevant, to 0.85%,which is a rather strong
effect. Clearly, all of these promising studies are still preliminary,
and before the results from large, ongoing studies (see below)
are available, no firm conclusion on the magnitude of the effect
can be drawn. However, it can be said that the principle of
improving diabetes by modulating IL-1b has been demon-
strated. Beyond this first conclusion, many additional avenues
are opening. Thus, the improvement in insulin secretion following
withdrawal of IL-1 antagonism may last at least 39 weeks (Cav-
elti-Weder et al., 2012; Larsen et al., 2009; Sloan-Lancaster
et al., 2013). This may result from the interruption of IL-1b auto-
induction (Bo¨ni-Schnetzler et al., 2008). Another aspect of IL-1
antagonism is lack of hypoglycemia induction. Indeed, limita-
tions of current treatments, such as insulin and sulfonylurea,
include the decrease in blood glucose levels beyond normal
values, causing significant untoward effects. In contrast, by
improving b cell function with IL-1 antagonism, it is expected
that the b cell will release insulin solely following metabolic stim-
ulation. Along this line, the number of hypoglycemic events was
not increased by IL-1 antagonists, despite a significant improve-
ment of glycemic control. Furthermore, the development of
humanized antibodies against IL-1b provides drugs with a half-
life of several weeks, allowing for monthly or even trimestral
dosing. Importantly, the drugs appear safe based on the experi-
ence gained from the increased use of IL-1 antagonism for
several additional therapeutic indications, including in more
than 100,000 patients with rheumatoid arthritis. Only rarely
have infections been reported, which appeared benign and
were easily controlled. Finally, many other complications of
diabetes may be caused or promoted by IL-1b-induced inflam-
mation, including nephropathy (Navarro-Gonza´lez and Mora-
Ferna´ndez, 2008) and cardiovascular complications (Berk
et al., 1990; Ridker et al., 1997). Based on this perspective, a
large-scale trial of IL-1b antagonism (canakinumab) has been
initiated (http://www.clinicaltrials.gov/ct2/show/NCT01327846?17, June 4, 2013 ª2013 Elsevier Inc. 865
Table 1. Clinical Studies Using Anti-Inflammatory Approaches to Treat Patients with Type 2 Diabetes
Mechanism Drug
Treatment
Duration Main Findings Remarks/Limits Source
IL-1 receptor
blockade
anakinra
(kineret)
13 weeks HbA1c Y; CRP Y;
insulin secretion [
dose not adapted
to body weight
Larsen et al., 2007
IL-1 receptor
blockade
anakinra
(kineret)
follow up for
39 weeks
sustained CRP Y;
insulin secretion [;
insulin requirement Y
follow-up study of the
one above (Larsen
et al., 2007)
Larsen et al., 2009
IL-1 receptor
blockade
anakinra
(kineret)
4 weeks insulin secretion [;
insulin sensitivity
unchanged
prediabetic patients;
underpowered study
(13 patients) and
short duration
van Asseldonk et al.,
2011
IL-1b antagonsim single dose of
anti-IL-1b antibody
(gevokizumab)
13 weeks HbA1c Y; CRP Y;
insulin secretion [
– Cavelti-Weder et al.,
2012
IL-1b antagonsim anti-IL-1b antibody
(canakinumab)
4 weeks insulin secretion [;
CRP Y
short duration Rissanen et al., 2012
IL-1b antagonsim anti-IL-1b antibody
(canakinumab)
16 weeks CRP Y; HbA1c Y;
insulin secretion [ (not
statistically significant)
underpowered for
low basal HbA1c
Ridker et al., 2012
IL-1b antagonsim anti-IL-1b antibody
(LY2189102)
12 weeks and
follow up for
24 weeks
HbA1c Y; CRP Y;
insulin secretion [
further improvement
of HbA1c at week 24
Sloan-Lancaster et al.,
2013
IKK-b-NF-kB
inhibition
salsalate 4 weeks FBG Y; CRP Y;
insulin sensitivity [;
adiponectin [
short duration Fleischman et al., 2008
IKK-b-NF-kB
inhibition
salsalate 2–4 weeks FBG Y;
CRP Y; adiponectin [
short duration Goldfine et al., 2008
IKK-b-NF-kB
inhibition
salsalate 1 week FBG Y; insulin [;
CRP Y
short duration Koska et al., 2009
IKK-b-NF-kB
inhibition
salsalate 12 weeks HbA1c Y; FBG Y;
triglyceride Y;
Adiponectin [
– Goldfine et al., 2010
IKK-b-NF-kB
inhibition
salsalate 12 weeks HbA1c Y; FBG Y;
insulin secretion [;
triglyceride Y
drug-naive patient;
strong effects on
gylcemia
Faqhihimani et al., 2011
IKK-b-NF-kB
inhibition
salsalate 12 weeks FBG Y; adiponectin [ prediabetic patients Goldfine et al., 2013
TNF-a antagonism single dose of anti-
TNF-a antibody
(CDP571)
4 weeks no effect on
insulin sensitivity
underpowered study
(ten patients) and
short duration
Ofei et al., 1996
TNF-a antagonism single dose of soluble
TNF- Receptor: Fc fusion
protein
(Ro 45-2081)
48 hours no effect on
insulin sensitivity
underpowered study
(seven patients) and
short duration
Paquot et al., 2000
TNF-a antagonism soluble TNF- receptor:
Fc fusion protein
(etanercept)
4 weeks CRP Y; insulin
secretion [;
no effect on
insulin sensitivity
underpowered study
(ten patients) and
short duration
Dominguez et al., 2005
TNF-a antagonism soluble TNF- receptor:
Fc fusion protein
(etanercept)
4 weeks CRP Y, adiponectine [;
LDL Y;
no effect on insulin
sensitivity
short duration Bernstein et al., 2006
Decrease of TNF-a
and IL-1b by an
unknown mechanism
of action
diacerein 8.5 weeks HbA1c Y; FBG Y;
insulin secretion [
drug-naive patient;
strong effects on
gylcemia
Ramos-Zavala et al.,
2011
HbA1c, glycated haemoglobin; IKK-b, IkB kinase-b; NF-kB, nuclear factor-kB; CRP, C-reactive protein; FBG, fasting blood glucose.
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Perspectiveterm=cantos&rank=1). This trial is now enrolling patients in >35
countries. It will randomly allocate 17,200 patients to placebo
or to canakinumab, with all of the participants followed prospec-
tively over an estimated 4 year period for the trial’s primary
endpoint (nonfatal myocardial infarction, nonfatal stroke, or car-
diovascular death) aswell as for new-onset diabetesmellitus and
diabetes progression. A specific substudy will assess insulin
secretion and sensitivity.
Salsalate
Salsalate is a prodrug of salicylic acid that inhibits NF-kB activity.
Several studies have clearly demonstrated its ability to lower
blood glucose levels and improve insulin sensitivity (Fleischman
et al., 2008; Goldfine et al., 2008, 2010, 2013), and a phase 3
study is ongoing (NCT00799643). Overall the effects are similar
to those observed with IL-1 antagonism. This is compatible
with the fact that IL-1b activity is largely mediated via NF-kB.
However, activation of NF-kB by means other than IL-1b may
arouse additional effects. Furthermore, the pharmacological
properties of salsalate, which is given orally and has a short
half-life requiring several daily doses, differs from anti-IL-1b
antibodies, which have a half-life of several weeks. This may
explain some differences observed between both treatments.
Indeed, while salsalate consistently improved insulin sensitivity,
the improvement in insulin secretion was more difficult to detect.
This is in contrast to IL-1 antagonism, which reliably leads to
improved insulin secretion, while the effect on insulin sensitivity
is not always detectable. Furthermore, while both drugs
decreased systemic inflammation, as reflected by normalization
of white blood cell counts, the effect on C-reactive protein was
more consistent with anti-IL-1b treatment. However, between
the different studies, there were important variances in the
design, the study population, the methods, and the endpoints.
Therefore, only direct comparative studies will disclose whether
these differences are real.
Anti-Inflammatory Drugs with Unclear Mechanisms
Diacerein is a drug frequently used in the treatment of joint dis-
ease due to its anti-inflammatory effects. Diacerein decreases
TNF-a and IL-1b, but the mechanism of this effect is unknown.
In a recent, promising clinical study, 40 patients with type 2 dia-
betes were randomized to receive diacerein or a placebo. After
two months of treatment, diacerein showed a profound effect
on blood glucose levels along with improved insulin secretion
(Ramos-Zavala et al., 2011). Other compounds with anti-inflam-
matory effects have been tested including AC-201, a compound
that apparently supresses IL-1b expression. Two phase 2 clinical
studies were conducted in patients with type 2 diabetes, and
both showed encouraging improvement in glycemia (http://
www.twipharma.com). For the time being, these studies should
be interpreted with caution, due to the limited information avail-
able in the public domain.
Interleukin-6
As mentioned above, IL-6 has pleiotropic effects. The possible
involvement of IL-6 in insulin resistance would argue in favor of
blocking its activation, while the opposite holds true for its insulin
sensitizing effects and for its effect on GLP-1-mediated insulin
secretion (Carey et al., 2006; Jansson and Wallenius, 2007;
Lazar, 2005; Mooney, 2007; Pedersen and Febbraio, 2007;
Sabio et al., 2008; Weigert et al., 2007; Wunderlich et al.,
2010). It is possible that, in healthy individuals, IL-6 is a beneficialregulator of glucose disposal, while in the context of obesity, IL-6
will promote the prevailing inflammation and precipitate insulin
resistance. However, this remains speculative, and due to the
complex effects of IL-6, clinical translation should await the
outcome of further studies clarifying the precise role of IL-6 in
metabolism and the development of drugs, allowing IL-6 effects
to be targeted to a specific tissue (Rose-John, 2012). Neverthe-
less, existing evidence is sufficient to advise a raise in circulating
levels of IL-6 viamuscle activity: the beneficial effects of exercise
in the prevention and treatment of diabetes is well documented,
though it remains to be shown that this is (partly) IL-6 dependent.
Off-Target Anti-Inflammatory Effects of Drugs Used in
Patients with Diabetes
Several drugs used with specific indications in patients with
type 2 diabetes have anti-inflammatory properties that may
contribute to their overall positive effects in outcome studies.
The most obvious example being acetylsalicylic acid, often pre-
scribed with the aim to inhibit platelet activation that may have
beneficial effects due to its anti-inflammatory feature. However,
it is unclear whether the low doses used are sufficient to have a
significant anti-inflammatory effect. Better substantiated are the
anti-inflammatory effects of statins. An indication was given by
the JUPITER study in which healthy persons without hyperlipid-
emia, but with elevated C-reactive protein levels, were treated
with rosuvastatin, which significantly reduced the incidence of
major cardiovascular events (Ridker et al., 2008).
Modulation of the renin-angiotensin system may also have
anti-inflammatory consequences beyond lowering blood pres-
sure. Several studies with angiotensin receptor blockers found
reduced serum levels of TNF-a, IL-6, and/or CRP in patients
with hypertension or type 2 diabetes (Fliser et al., 2004; Manabe
et al., 2005; Pavlatou et al., 2011). Interestingly, the angiotensin II
receptor type 1 is expressed in several immune cell populations,
and its signaling regulates T cells as well as monocytes and
macrophages (Garcia, 2010). In concordance with this, Fujisaka
et al., (2011) show that the angiotensin receptor blocker telmisar-
tan modulates adipose tissue macrophage polarization to an
anti-inflammatory M2 state in HFD mice. Supporting these
observations, several clinical trials have indicated that angio-
tensin-converting enzyme inhibitors and angiotensin receptor
blockers reduce the incidence of new-onset type 2 diabetes in
high-risk populations. This protective effect has been attributed
not only to the blood pressure-lowering activity, but also to
improved muscle insulin signaling and adipocyte function (Jan-
deleit-Dahm et al., 2005; van der Zijl et al., 2012). It remains
to be shown whether this protective effect is also due to anti-
inflammatory effects.
Additional anti-inflammatory drugs currently used for other
indications may be tested in the near future. These drugs should
be selected on the basis of proven safety profiles in patients. An
intriguing example is amlexanox, a drug approved for the treat-
ment of aphthous ulcers and bronchial asthma, which has
recently been shown to increase energy expenditure and insulin
sensitivity (Reilly et al., 2013).
Alteration of Gut Microbiota in Obesity and Type 2
Diabetes—Strategies for Modulation
Gutmicrobiotamay contribute to obesity and type 2 diabetes (for
detailed review, see the article by Cox and Blaser [2013] in this
issue of Cell Metabolism). Pioneering studies showed thatCell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc. 867
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gut microflora. Ley et al. described that both ob/ob mice and
obese subjects were associated with decreased numbers of
Bacteroidetes and increased numbers of Firmicutes compared
to lean counterparts (Ley et al., 2005, 2006). In rodents, the num-
ber of Bifidobacteria was also markedly reduced upon diet-
induced obesity (Cani et al., 2007). Such differences in the gut
microbiota were shown to promote an altered energy harvest
from the diet, essentially through breakdown of otherwise indi-
gestible dietary polysaccharrides. The use of germ-free mouse
models or the administration of antibiotics to eliminate gutmicro-
biota in conventionally raised mice both lowered body weight
and fat mass during diet-induced obesity (Ba¨ckhed et al.,
2004; Cani et al., 2008). Besides, colonization of germ-free
mice with microbiota derived from obese mice exhibited greater
adiposity than with microbiota derived from lean mice (Turn-
baugh et al., 2006). Based on these observations, the question
arises as to howmodulations of the gutmicrobiotia could directly
influence obesity-induced metabolic outcomes. One hypothesis
suggests that high-fat feeding results in LPS-rich microbiota and
enhanced LPS translocation into the circulation through
increased intestinal permeability (Cani et al., 2007, 2008). The
composition of the gut microbiota resulted in LPS-dependent
macrophage accumulation in adipose tissue, whereas no corre-
lation was found with systemic glucose metabolism (Caesar
et al., 2012). Thus, strategies to manipulate gut microbiota could
be an additional approach for the treatment of obesity and type 2
diabetes. Interestingly, beneficial effects of lean fecal microbiota
transplantation were recently reported in subjects with themeta-
bolic syndrome, paving the way to the development of new ther-
apeutic designs (Vrieze et al., 2012).
Combined Anti-Inflammatory Treatment
There are several reasons to combine different anti-inflammatory
drugs in future treatment strategies of type 2 diabetes. Many
inflammatory pathways are involved in the pathogenesis of the
disease, and it is unlikely that a single drug will be able to modu-
late all of them. Some treatments seem to be more effective in
improving insulin secretion (anti-IL-1), while others may impact
primarily insulin-sensitive tissues (anti-TNF-a, salsalate). Finally,
by combining drugs that have a similar target via modulation of
different pathways, the amount of untoward effects may be
reduced since the off-target effects of the various drugs differ.
Safety Issues
The immune system has multiple tasks including host defense
against microbes and clearance of malignant cells. By interfering
with this system, the danger of infection or cancer may increase.
These and other possible untoward effects can be limited either
by using weaker anti-inflammatory drugs or by interfering with a
very precise pathway, which plays a central role in a specific
inflammatory disease but is less important for host defense or
cancer surveillance. Both options exist. Indeed, salsalate acts
on multiple pathways, including NF-kB, but is not very potent.
This may explain the relative safety of the drug, which can be
acquired without a prescription (over-the-counter drug). Other
drugs, such as anti-TNF-a antibodies and IL-1 antagonists, effi-
ciently block their respective target molecules and are highly
specific. This may explain the somewhat unexpected, excellent
safety profile of these drugs. Indeed, both types of drugs have
extensively been used for the treatment of several diseases868 Cell Metabolism 17, June 4, 2013 ª2013 Elsevier Inc.(including patients with rheumatoid arthritis in combination with
immunosuppressive drugs) and showed very limited side
effects. The main remaining concern is the acceleration of tuber-
culosis upon TNF-a inhibition, which largely can be avoided by
screening the patients for the disease before treatment initiation.
IL-1 antagonism minimally increases the incidence of acute
infections, which are readily controlled by classic treatments.
Due to the specificity of the treatment, it is conceivable that other
cytokines compensate to enable an adequate host defense.
Another hypothesis is that chronic activation of the innate
immune system per se lowers host defense; therefore, restoring
homeostasis via specific cytokine antagonistsmay even improve
host defense. However, this is still speculative, and until long-
term follow up is available, some safety concerns remain.
Outlook and Conclusions
Obesity and diabetes have reached epidemic dimensions. In the
history of medicine, epidemics have only been successfully alle-
viated via prevention. However, for the affected individuals,
additional causative treatment is needed in order to stop the pro-
gression of the disease. Inflammation emerges as an important
pathogenic pathway not only in the development of diabetes
itself but also in the development of its complications. Therefore
anti-inflammatory treatment may help affected patients by pre-
venting both the onset and progression of diabetes and its asso-
ciated comorbidities. However, the immune system is a complex
network with beneficial and deleterious elements that show up
depending on duration, level, and path of activation and genetic
background. It would therefore be naive to expect that single and
uniform anti-inflammatory interventions normalize the pathologic
activity of the immune system. Rather, we expect multiple inter-
ventions with adapted doses and duration. In the meantime, we
should be cautious with the interpretation of the first pilot studies
and avoid rapid conclusions on the potential of anti-inflamma-
tory treatment of metabolic disease. For the time being, we
should be encouraged by the positive outcome of clinical
proof-of-concept studies that show that modulation of the
immune system can improve glycemia (Fleischman et al.,
2008; Larsen et al., 2007).
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